Product Description
Mechanisms of Action: ELA Modulator
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Percutaneous,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Protara Therapeutics
Company Location: NEW YORK NY 10010
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Kidney Failure, Chronic|Venous Insufficiency|Arteriovenous Fistula
Phase 1: Peripheral Arterial Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PRT-201-115 | P1 |
Completed |
Peripheral Arterial Disease |
2019-04-30 |
22% |
| PRT-201-110 | P1 |
Withdrawn |
Peripheral Arterial Disease |
2019-04-30 |
22% |
| PATENCY-2 | P3 |
Completed |
Arteriovenous Fistula|Kidney Failure, Chronic|Venous Insufficiency |
2018-02-01 |
|
| PATENCY-1 | P3 |
Completed |
Kidney Failure, Chronic|Arteriovenous Fistula|Venous Insufficiency |
2016-12-01 |